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ABSTRACT: Background: Glucocerebrosidase
gene mutations are a common genetic risk factor for
Parkinson’s disease. They exhibit incomplete pene-
trance. The objective of the present study was to
measure microglial activation and dopamine integrity
in glucocerebrosidase gene mutation carriers without
Parkinson’s disease compared to controls.
Methods: We performed PET scans on
9 glucocerebrosidase gene mutation carriers without
Parkinson’s disease and 29 age-matched controls.
We measured microglial activation as 11C-(R)-
PK11195 binding potentials, and dopamine terminal
integrity with 18F-dopa influx constants.
Results: The 11C-(R)-PK11195 binding potential was
increased in the substantia nigra of
glucocerebrosidase gene carriers compared with con-
trols (Student t test; right, t = −4.45, P = 0.0001). Sta-
tistical parametric mapping also localized significantly
increased 11C-(R)-PK11195 binding potential in the
occipital and temporal lobes, cerebellum, hippocam-
pus, and mesencephalon. The degree of hyposmia
correlated with nigral 11C-(R)-PK11195 regional bind-
ing potentials (Spearman’s rank, P = 0.0066). Mean
striatal 18F-dopa uptake was similar to healthy controls.
Conclusions: In vivo 11C-(R)-PK11195 PET imaging
detects neuroinflammation in brain regions suscepti-
ble to Lewy pathology in glucocerebrosidase gene
mutation carriers without Parkinson’s. © 2020 The
Authors. Movement Disorders published by Wiley
Periodicals LLC on behalf of International Parkinson
and Movement Disorder Society
Key Words: Parkinson’s disease; microglia; sub-
stantia nigra; glucocerebrosidase; positron emission
tomography
The glucocerebrosidase gene (GBA) encodes the lyso-
somal hydrolase glucocerebrosidase. In the biallelic
(homozygous or compound heterozygous) state, GBA
mutations may cause Gaucher disease (GD) which leads
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly
cited.
*Correspondence to: Prof. Anthony HV Schapira, UCL, Institute of Neu-
rology, Royal Free Campus, Rowland Hill Street, Hampstead, London
NW3 2PF, UK; E-mail: a.schapira@ucl.ac.uk
†Joint first authorship.
‡Joint last authorship.
Relevant conflicts of interest/financial disclosures: There were no
conflicts of interest. S.M. is a National Institute for Health Research–
supported clinical lecturer.
Funding agencies: This research was funded by the Medical Research
Council (MR/J009660/1 COEN 1), MRC Experimental Medicine
(MR/M006646/1), and Joint Programme Neurodegenerative Disease
Research (MR/N028651/1) and was supported by the National Institute
for Health Research University College London Hospitals Biomedical
Research Centre. SM is a National Institute for Health Research
supported clinical lecturer. Independent Research Fund Denmark,
Lundbeck Foundation, Kattan Trust (285), and Joint Programme Neuro-
degenerative Disease Research (MR/N028651/1). Funders had no role
in data analysis and did not have access to the data set.
Received: 15 July 2020; Revised: 11 October 2020; Accepted: 19
October 2020
Published online 5 December 2020 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.28375
774 Movement Disorders, Vol. 36, No. 3, 2021
M U L L I N E T A L
to glucosylceramide accumulation in visceral organs
and, in a minority of cases, the central nervous system
(neuronopathic GD). GBA mutations are the most sig-
nificant genetic risk factor for Parkinson’s disease
(PD) and dementia with Lewy bodies (DLB)1-3; how-
ever, penetrance is only 10%–30%.4-6 PD patients car-
rying a GBA mutation have an earlier disease onset and
a higher risk of dementia.7
At postmortem, α-synuclein aggregations identical to
those found in idiopathic PD1 and DLB8 are present in
GBA-PD subjects. Asymmetrically reduced striatal 18F-
dopa uptake,9,10 striatal dopamine transporter
binding,11,12 and an altered striatal asymmetry index13
have been reported in PD patients with GBA muta-
tions. Conversely 123I-isoflupane dopamine transporter
uptake has been demonstrated to be upregulated in
non-PD GBA carriers compared with controls and is
higher in GBA PD compared to idiopathic PD
cases.14,15 GBA mutation carriers without PD exhibit
prodromal PD features,16-19 which progress with
time.20
Glial activation has been demonstrated in postmor-
tem PD brains.21,22 Nigral microglial activation along
with reduced striatal 18F-Dopa uptake is present in idi-
opathic rapid eye movement sleep behavior disorder
(RBD).23 It is also a feature of neuronopathic GD at
postmortem8 and in GD mouse models.24 No studies
have investigated in vivo the presence of brain micro-
glial activation in GBA mutation carriers and related
this to the presence of striatal dopaminergic dysfunc-
tion. We therefore measured 11C-(R)-PK11195 regional
binding potentials (BPND) and
18F-dopa Ki in GBA
mutation carriers without evidence of Parkinson’s
disease.
Methods
Recruitment and Clinical Assessments
Between 2015 and 2016, 9 biallelic (homozygous or
compound heterozygous) or heterozygous carriers of
GBA mutations were recruited from University College
London, UK (see Table 1 for characteristics). All sub-
jects had exons 1–11 of the GBA gene sequenced
(Table 1). Biallelic carriers had type 1 GD, whereas het-
erozygous carriers were drawn from GD kindreds. No
subjects met PD (UK Brain Bank) diagnostic criteria,
and none were genetically related. Two of 5 GD
patients were receiving enzyme replacement therapy
(ERT; velaglucerase 800 IU weekly and 4000 IU
monthly) and 3 of 5 substrate reduction therapy (SRT:
eligustat 84 IU twice daily in 2 of 3, miglustat 300 mg
once daily in 1 of 3). Both SRT and ERT were adminis-
tered throughout the duration of the study. Ethical
approval was obtained from London, UK
(10/H0720/21), and Midtjylland, Denmark (M-
2014-397-14), research ethics committees.
Each GBA carrier had 11C-(R)-PK11195 and 18F-
dopa PET, an MRI, and neurological examination. Pro-
dromal PD features were rated with the University of
Pennsylvania Smell Identification Test (UPSIT), Mon-
treal cognitive assessment, RBD questionnaire
(RBDSQ), PD Non-Motor Symptoms Scale, the Move-
ment Disorder Society Unified Parkinson’s Disease Rat-
ing Scale (MDS-UPDRS) parts II and III, and Beck’s
Depression Inventory.
All scans and examinations were performed at Aar-
hus University Hospital, Denmark. GBA carrier PET
findings were compared with in-house PET data from
29 age-matched healthy controls (20 had 11C-[R]-
PK11195 BPND PET, and 9 had
18F-dopa PET) rec-
ruited for a previously published study.25 Assessments
of control prodromal PD features were not available.
PET and MRI
We performed prespecified region-of-interest (ROI)
analyses comparing GBA mutation carriers with con-
trols. Selected ROIs were the substantia nigra (SN),
putamen, and caudate for 11C-(R)-PK11195 BPND and
the putamen and caudate for 18F-dopa Ki. We per-
formed statistical parametric mapping (SPM) of 11C-
(R)-PK11195 uptake across all brain voxels. Technical
details of the PET and MRI scanning and analysis pro-
cedures are available in the supplementary materials.
Statistics
For the ROI analyses, statistical calculations and graphs
were produced with Stata v14.2 software (StataCorp., Col-
lege Station, TX). The 18F-dopa Ki and
11C-(R)-PK11195
BPND values from specified ROIs were compared in carrier
and control groups using the Student t test (P < 0.05). When
there was a significant difference in 11C-(R)-PK11195 BPND
between the GBA and control groups, secondary analyses
correlating PD prodromal features with 11C-(R)-
PK11195BPND were undertaken (Spearman’s rank: all clini-
cal scales were non normally distributed, P < 0.05). A
Bonferroni correction was applied to all significant results.
Results
Participants
Participant characteristics are listed in Table 1. Nine GBA
mutation carriers (5 biallelic and 4 heterozygous) were selected
on the basis of their genotype and the absence of PD features.
Two age-matched control groups (20 for 11C-(R)-PK11195
BPND PET and 9 for
18F-dopa PET) were included in the final
GBA analysis. Some GD patients had musculoskeletal prob-
lems typical of GD reflected in raised MDS UPDRS III scores,
but these were not specific for PD. This reflects the limitations
of the MDS UPDRS when used in the context of non-PD
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comorbidities and applied to subjects without diagnosed
PD. No participants had a bradykinetic or rigid syndrome on
expert examination. There were no missing data.
Substantia Nigra 11C-(R)-PK11195 BPND Is
Increased in GBA+ Individuals Compared With
Controls
ROI analysis localized a significant increase in mean
nigral 11C-(R)-PK11195 BPND of the GBA carriers com-
pared with controls (Student t test, t = −4.45, P = 0.0001;
Tables S1 and S2). Statistical significance was retained
after correction for multiple comparisons (Table S2). For
the GBA mutation carriers, mean SN 11C-(R)-PK11195
BPND was 0.15 ± 0.08 compared with −0.01 ± 0.09 for
the control group (Table S1 and Fig. 1A). Interestingly,
heterozygous carriers had disproportionately higher BPND
than biallelic (GD) patients (Table S1 and Fig. 1A).
11C-(R)-PK11195 BPND Correlates With
Olfactory Deficit in GBA+ Individuals
There was a negative correlation between nigral 11C-
(R)-PK11195 BPND and UPSIT scores in GBA muta-
tion carriers (Spearman’s rank, P = 0.0066; Table S2
and Fig. 1D), which did not survive correction for mul-
tiple comparisons (Table S2).
Upregulated Cortical, Hippocampal,
and Mesencephalon 11C-(R)-PK11195 BPND in
GBA+ Group
SPM-localized clusters of voxels with significantly
increased 11C-(R)-PK11195 BPND in GBA carriers
TABLE 1. Characteristics of control and GBA carrier groups
Biallelic GBA (n = 5) Heterozygous GBA (n = 4) Combined GBA (n = 9) 11C-(R)-PK11195 controls (n = 20) 18F-Dopa controls (n = 9)
Age, years 62.6 (2.9) 63.3 (7.7) 62.9 (2.9) 66.8 (6.0) 64.6 (3.6)
Male, % 40.0 50.0 44.4 60.0 100.0
UPSIT 33.6 (1.1) 31.5 (3.9) 32.7 (2.7)
MoCA 27.4 (1.9) 27.8 (2.2) 27.6 (1.9)
MDS UPDRS II 2.0 (2.1) 3.0 (3.6) 2.4 (2.7)
MDS UPDRS III 12.8 (10.4) 4.5 (2.4) 9.1 (8.7)
BDI 2.6 (2.7) 4.0 (1.4) 3.2 (2.2)
NMSS 13.8 (9.2) 17.0 (10.4) 15.2 (9.3)
RBDSQ 2.0 (1.9) 4.5 (2.4) 3.1 (2.4)
Mutations of GBA group
Gaucher disease Enzyme replacement therapy Substrate reduction therapy
N370s/L444Pa Yes No Yes
N370S/IVS2 + 1a No No Yes
N370S/F216Y Yes Yes No
N370S/R359Xb Yes No Yes
N370S/V447E Yes Yes No
RecNcil (L444P/A456P/V460V)a/wt No No No
N370S/wt No No No
N370S/wt No No No
V394La/wt No No No
Clinical scores of GBA carriers
Participant MDS UPDRS II MDS UPDRS III MoCA UPSIT BDI NMSS RBDSQ
1 0 2 30 37 4 15 7
2 0 3 25 30 2 4 2
3 2 4 30 35 2 8 1
4 5 29 26 32 3 13 4
5 0 4 26 33 7 28 4
6 3 11 29 34 1 16 1
7 0 7 27 31 5 29 0
8 2 6 29 28 5 20 1
9 0 16 26 34 0 4 0
GBA, glucocerebrosidase; PD, Parkinson’s disease; MDS UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating Scale; NMSS, Non-Motor
Symptoms Scale; MMSE, Mini–Mental State Examination; MoCA, Montreal Cognitive Assessment; BDI, Beck’s Depression Index; RBDSQ, REM Sleep Behavior
Disorder Questionnaire.
For demographics, results are mean (SD).
aSevere mutation of GBA carrier group.
bNull mutation of GBA carrier group.
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bilaterally in the occipital and temporal cortices, cere-
bellum, left hippocampus, and central and anterior
mesencephalon (Table S3 and Fig. 1B,C). No brain
regions showed reduced 11C-(R)-PK11195 BPND com-
pared with controls.
No Difference in Mean 18F-Dopa Ki Between
GBA+ and Control Participants
The GBA carriers showed no significant decreases in
mean 18F-dopa Ki across striatal ROIs compared with
controls (Tables S1 and S2, Fig. S1). Two participants
had putamen and/or caudate 18F-dopa Ki more than
2 SDs below the control mean (Table S4). Greater vari-
ance in 18F-dopa Ki (see Table S1) was seen in the GBA
group (SD of 0.002 in the putamen and caudate com-
pared with SD of 0.001 in controls). Post hoc analysis
(Student t test) comparing the anterior, medial, and
posterior putamen did not show any significant mean
differences between GBA mutation carriers and
controls.
No Correlation Between Nigral 11C-(R)-
PK11195 BPND and
18F-Dopa Ki in GBA+ Group
There was no association between the SN 11C-(R)-
PK11195 BPND and putamen or caudate (Table S2)
18F-dopa Ki in the GBA group.
Discussion
Our data indicate that both heterozygous and biallelic
GBA mutation carriers can have increased 11C-(R)-
PK11195 BPND in brain regions susceptible to Lewy body
formation.26 It is unclear whether this is a cytotoxic or
neuroprotective process. Only 10%–30% of GBA muta-
tion carriers will develop PD. It is therefore unlikely that
all the participants in this study will convert. Which GBA
carriers are likely to progress to PD and the mechanisms
underlying this conversion are of particular interest.
11C-(R)-PK11195 BPND values in the SN correlated
with UPSIT scores, suggesting that those GBA carriers
who have reduced olfactory function have higher nigral
inflammation. Correlation of striatal 11C-(R)-PK11195
FIG. 1. (A) Top left, box and dot plots of 11C-PK11195 binding potential (BPND) in the substantia nigra of GBA+ heterozygous carriers (white circles),
biallelic GBA+ carriers (black circles), and controls (hollow black diamonds). Please note data points are offset across x axis for ease of interpretation.
Middle line is median, box is interquartile range. (B) Top right, 11C-PK11195 binding potential (BPND) in GBA carriers > controls. Colored areas depicted
on the single-subject brain template illustrate clusters of voxels of 11C-PK11195 binding potential (BPND) surviving P < 0.05 with family-wise error rate
(FWE) correction in the brain stem region of GBA+ carriers compared with control subjects. Non–brain stem clusters are masked. GBA, n = 9; controls,
n = 20. (C) Bottom left, 11C PK11195 binding potential (BPND) in GBA carriers > controls. Red areas depicted on the brain surface template illustrate
clusters of voxels of 11C-PK11195 BPND surviving P < 0.05 with FWE correction in cortical regions of GBA+ carriers compared with control subjects.
GBA+, n = 9; controls, n = 20. (D) Bottom right, scatterplots of 11C-PK11195 BPND in the substantia nigra of GBA+ carriers against University of Penn-
sylvania Smell Identification Test (UPSIT) score. GBA+ heterozygous carriers (white), biallelic GBA+ carriers (black). [Color figure can be viewed at
wileyonlinelibrary.com]
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BPND with age and MDS UPDRS III score has also been
shown in early PD cases.27
Despite mean nigral 11C-(R)-PK11195 BPND being
increased in the GBA group, no significant reduction in
mean putamen 18F-dopa uptake was seen. It is known
that 18F-dopa lacks the sensitivity to detect early dopami-
nergic dysfunction because of compensatory upregulation
of dopa decarboxylase in the remaining terminals. Early
reductions may be better detected with dopamine trans-
porter markers.28,29 Our finding of normal striatal
F-dopa uptake in GBA carriers may not necessarily
equate to normal dopamine terminal function, although
noGBA carrier exhibited clinical features of PD.
Interestingly 18F-dopa Ki was more variable in the
GBA group compared with controls. Recently, 184 non-
manifesting GBA carriers were reported to have
increased dopamine transporter binding across striatal
regions.15 This is in line with an increase in striatal 18F-
dopa Ki found in a portion of our GBA+ cases. It has
been reported that 11C-(R)-PK11195 binding to
microglia “burns out” as amyloidosis in early
Alzheimer’s disease advances30 but increases again as
tau tangles form.31,32 A biphasic trajectory could
explain the lack of correlation between 18F-dopa Ki and
11C-(R)-PK11195 BPND in our data set.
Limitations
The relatively small sample size, its cross-sectional
design, and the unknown future disease status of GBA
mutation carriers are limitations. We acknowledge that
GBA mutations exhibit a variable penetrance and phe-
notype, in terms of both PD and GD. Reproducing
these results in larger (ideally prospective) and more
genotypically and phenotypically homogenous cohorts
is needed. Nevertheless, we believe these are important
and highly relevant pilot data that will inform the
design of future studies.
The 11C-PK11195 BPND has high nonspecific bind-
ing, which provides a lower specific-to-background
PET signal ratio than newer markers of activated
microglia; therefore, our results may underestimate glial
activation. This study used 11C-(R)-PK11195 BPND as a
marker of the translocator protein (TSPO) expressed by
the mitochondria of activated microglia, and, in con-
trast to newer TSPO tracers available, the binding is
not influenced by the polymorphism of the TSPO
expressed by individuals. The limitations of supervised
cluster analysis in conditions with possible widespread
microglial activation should also be acknowledged, as it
could lead to an underestimation of 11C-(R)-PK11195
BPND, particularly in small ROIs.
Three of 5 and 2 of 5 subjects were taking substrate
reduction therapy or enzyme replacement therapy (ERT),
respectively. The former is under evaluation as a PD neu-
roprotective agent (clinicaltrials.gov, NCT02906020).
ERT is not thought to cross the blood–brain barrier,
although 1 report suggests a portion may.33 We cannot
exclude the possibility that the reduced nigral and puta-
men 11C-(R)-PK11195 BPND in biallelic compared with
heterozygous cases could represent suppression of glial
activation by these drugs.
Conclusions
Our findings indicate that GBA mutations are associ-
ated with microglial activation in Lewy-susceptible
brain regions in subjects without either a prodromal or
clinical diagnosis of PD. Further studies are required to
assess whether 11C-(R)-PK11195 BPND PET, (with or
without additional biomarkers) can predict GBA carrier
conversion to PD and striatal dopamine loss.
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